Inovio Pharmaceuticals stock falls 1.79% and underperforms competitors
Updated
Updated · MarketWatch · May 1
Inovio Pharmaceuticals stock falls 1.79% and underperforms competitors
8 articles · Updated · MarketWatch · May 1
Shares closed at $1.10 as the Nasdaq rose 0.89% to 25,114.44 and the Dow fell 0.31% to 49,499.27 in a mixed US session.
The stock finished 63.07% below its 52-week high of $2.98 reached on 9 September. Johnson & Johnson fell 1.16%, Pfizer dropped 1.39%, and Statera Biopharma was unchanged.
Trading volume was 1.1 million shares, about 650,054 below Inovio's 50-day average of 1.8 million, indicating lighter-than-usual activity during the decline.
Facing an FDA-approved rival, can Inovio's new therapy carve out a space in the rare disease market?
With cash dwindling and the FDA skeptical, can Inovio's lead drug win its high-stakes approval battle?